| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Uremia | D014511 | 33 associated lipids |
| Colitis, Ulcerative | D003093 | 24 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Kidney Failure, Chronic | D007676 | 51 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Hypoxia | D000860 | 23 associated lipids |
| Arrhythmias, Cardiac | D001145 | 42 associated lipids |
| Hypercalcemia | D006934 | 13 associated lipids |
| Neovascularization, Pathologic | D009389 | 39 associated lipids |
Platelet activating factor
Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
Cross Reference
Introduction
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Platelet activating factor?
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
PubChem Associated disorders and diseases
What pathways are associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Platelet activating factor?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Platelet activating factor?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Platelet activating factor?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Platelet activating factor?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Platelet activating factor?
Knock-out
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Platelet activating factor
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Kakishita E et al. | Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood. | 1990 | Thromb. Res. | pmid:2082481 |
| Chang GT et al. | Purification and characterization of a new anticoagulant protein, PP27, from placenta. | 2005 | Thromb. Res. | pmid:16122555 |
| Simon MF et al. | Effect of BN 52021, a specific antagonist of platelet activating factor (PAF-acether), on calcium movements and phosphatidic acid production induced by PAF-acether in human platelets. | 1987 | Thromb. Res. | pmid:3576518 |
| Alam I and Silver MJ | Metabolism of 1-alkyl-2-acyl-GPC in human platelets in response to stimulation by thrombin. | 1987 | Thromb. Res. | pmid:3576519 |
| Liu X et al. | Ginkgolide B inhibits platelet release by blocking Syk and p38 MAPK phosphorylation in thrombin-stimulated platelets. | 2014 | Thromb. Res. | pmid:25223809 |
| Bretschneider E et al. | ADP-, PAF- and adrenaline-induced platelet aggregation and thromboxane formation are not affected by a thromboxane receptor antagonist at physiological external Ca++ concentrations. | 1994 | Thromb. Res. | pmid:7992234 |
| Jones KP et al. | Salivary PAF in acute myocardial infarction and angina: changes during hospital treatment and relationship to cardiac enzymes. | 1994 | Thromb. Res. | pmid:7992251 |
| Juhan-Vague I et al. | Possible participation of adenosine 5'-diphosphate, arachidonic acid and paf-acether in the platelet pro-aggregating effect of uncontrolled insulin-dependent diabetic erythrocytes in vitro. | 1985 | Thromb. Res. | pmid:3923649 |
| Westwick J et al. | Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. | 1986 | Thromb. Res. | pmid:3715810 |
| Ishii H et al. | Thiolprotease inhibitor, EST, can inhibit thrombin-induced platelet activation. | 1990 | Thromb. Res. | pmid:2382255 |
| Hofmann B et al. | Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets. | 1988 | Thromb. Res. | pmid:3381200 |
| Heinrich J and Zimmermann RE | Compound 48/80 is a potent inhibitor of human platelet aggregation antagonizing the calmodulin-dependent platelet reaction in vitro. | 1984 | Thromb. Res. | pmid:6523451 |
| Hwang SB et al. | Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets. | 1984 | Thromb. Res. | pmid:6429890 |
| Janero DR et al. | Specific binding of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) to the intact canine platelet. | 1988 | Thromb. Res. | pmid:3413730 |
| Moon DG et al. | Platelet activating factor and sheep platelets: a sensitive new bioassay. | 1990 | Thromb. Res. | pmid:2326773 |
| Valone FH and Johnson B | Decay of the activating signal after platelet stimulation with 1-0-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine: changes in calcium permeability. | 1985 | Thromb. Res. | pmid:4082115 |
| Leoncini G et al. | Hyperactivity and increased hydrogen peroxide formation in platelets of NIDDM patients. | 1997 | Thromb. Res. | pmid:9175236 |
| Despotis GJ et al. | Effects of platelets and white blood cells and antiplatelet agent C7E3 (Reopro) on a new test of PAF procoagulant activity of whole blood. | 1997 | Thromb. Res. | pmid:9175242 |
| Avdonin PV et al. | Blocking of the receptor-stimulated calcium entry into human platelets by verapamil and nicardipine. | 1988 | Thromb. Res. | pmid:3232128 |
| Lecompte T et al. | Aequorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation-dependent calcium movement in response to ADP. | 1990 | Thromb. Res. | pmid:2117306 |
| Mabilat-Pragnon C et al. | Urokinase localization and activity in isolated eosinophils. | 1997 | Thromb. Res. | pmid:9526961 |
| Patterson WR et al. | Aggregation of killer whale platelets. | 1993 | Thromb. Res. | pmid:8327987 |
| Inoue Y et al. | Effect of a platelet activating factor antagonist and antithrombin III on septicemia and endotoxemia in rats. | 1991 | Tohoku J. Exp. Med. | pmid:2063402 |
| Nishihira J et al. | Purification and characterization of the specific binding protein for platelet activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) from human platelets. | 1985 | Tohoku J. Exp. Med. | pmid:3001971 |
| Isobe J and Mizuno A | Aspects of PAF (platelet activating factor)-induced aggregation by using rabbit platelets. | 1982 | Tokushima J. Exp. Med. | pmid:7170716 |
| Ezoulin MJ et al. | Study of PMS777, a new type of acetylcholinesterase inhibitor, in human HepG2 cells. Comparison with tacrine and galanthamine on oxidative stress and mitochondrial impairment. | 2006 | Toxicol In Vitro | pmid:16472967 |
| Baskin SI et al. | The effects of EDRF/NO releasers or calcium ionophore A23187 on cyanide toxicity in mice. | 1996 | Toxicol. Appl. Pharmacol. | pmid:8806852 |
| Wright DT et al. | Ozone stimulates release of platelet activating factor and activates phospholipases in guinea pig tracheal epithelial cells in primary culture. | 1994 | Toxicol. Appl. Pharmacol. | pmid:8048050 |
| Nomura DK et al. | Dual roles of brain serine hydrolase KIAA1363 in ether lipid metabolism and organophosphate detoxification. | 2008 | Toxicol. Appl. Pharmacol. | pmid:18164358 |
| Samet JM and Friedman M | Effect of ozone on platelet activating factor metabolism in phorbol-differentiated HL60 cells. | 1992 | Toxicol. Appl. Pharmacol. | pmid:1440609 |
| Hanslik T et al. | Effect of the platelet activating factor antagonist BN52021 in rabbits: role in gentamicin nephrotoxicity. | 1994 | Toxicol. Appl. Pharmacol. | pmid:8079343 |
| Ramos G et al. | Platelet activating factor receptor binding plays a critical role in jet fuel-induced immune suppression. | 2004 | Toxicol. Appl. Pharmacol. | pmid:15020195 |
| Feuerstein G et al. | Protective effect of a PAF-acether antagonist, BN 52021, in trichothecene toxicosis. | 1987 | Toxicol. Lett. | pmid:3660430 |
| Bailie MB et al. | Platelet activating factor receptor blockade alone or in combination with leukotriene synthesis inhibition does not ameliorate alpha-naphthylisothiocyanate-induced hepatotoxicity. | 1996 | Toxicol. Lett. | pmid:8614909 |
| Mahgoub AA | Thymoquinone protects against experimental colitis in rats. | 2003 | Toxicol. Lett. | pmid:12749817 |
| Flaherty MM et al. | Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice. | 2012 | Toxicol. Sci. | pmid:22025730 |
| Grandoni KM et al. | Trichothecene mycotoxins inhibit phosphoinositide hydrolysis in bovine platelets stimulated with platelet activating factor. | 1992 | Toxicology | pmid:1311467 |
| Pearson JM et al. | Neither platelet activating factor nor leukotrienes are critical mediators of liver injury after lipopolysaccharide administration. | 1997 | Toxicology | pmid:9231696 |
| Gambero A et al. | Signalling pathways regulating human neutrophil migration induced by secretory phospholipases A2. | 2004 | Toxicon | pmid:15450921 |
| Teixeira CF et al. | Hyperalgesia induced by Bothrops jararaca venom in rats: role of eicosanoids and platelet activating factor (PAF). | 1994 | Toxicon | pmid:8052996 |
| Shiroma N et al. | Haemodynamic and haematologic effects of Acanthaster planci venom in dogs. | 1994 | Toxicon | pmid:7846692 |
| Havt A et al. | The renal effects of Bothrops jararacussu venom and the role of PLA(2) and PAF blockers. | 2001 | Toxicon | pmid:11600146 |
| Castro-Faria-Neto HC et al. | Pro-inflammatory activity of enterolobin: a haemolytic protein purified from seeds of the Brazilian tree Enterolobium contortisiliquum. | 1991 | Toxicon | pmid:1796477 |
| Yara A et al. | Cardiovascular effects of Acanthaster planci venom in the rat: possible involvement of PAF in its hypotensive effect. | 1992 | Toxicon | pmid:1440631 |
| Rees RS et al. | Plasma components are required for platelet activation by the toxin of Loxosceles reclusa. | 1988 | Toxicon | pmid:3245050 |
| Freire-Maia L and de Matos IM | Heparin or a PAF antagonist (BN-52021) prevents the acute pulmonary edema induced by Tityus serrulatus scorpion venom in the rat. | 1993 | Toxicon | pmid:8266352 |
| Tai H et al. | TMVA, a snake C-type lectin-like protein from Trimeresurus mucrosquamatus venom, activates platelet via GPIb. | 2004 | Toxicon | pmid:15501291 |
| Melo RC et al. | Intragranular vesiculotubular compartments are involved in piecemeal degranulation by activated human eosinophils. | 2005 | Traffic | pmid:16138901 |
| Guerrant RL et al. | Diarrhea, demography and cell signaling: lessons from microbial toxins. | 1997 | Trans. Am. Clin. Climatol. Assoc. | pmid:9108674 |
| Shukla SD et al. | Response to platelet-activating factor in human platelets stored and aged in plasma. Decrease in aggregation, phosphoinositide turnover, and receptor affinity. | 1989 Jul-Aug | Transfusion | pmid:2546298 |